Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773601 | 1.00 | SLC7A5 (0.53) | SLC7A5ESR1ESR2FOLH1TAAR1 | |
| SCHEMBL6300076 | 1.00 | SLC7A5 (0.53) | SLC7A5ESR1ESR2FOLH1TAAR1 | |
| SCHEMBL11710892 | 0.87 | ADAMTS5 (0.50) | SLC7A5FOLH1ADAMTS5POLB | |
| SCHEMBL31114841 | 0.87 | ADAMTS5 (0.50) | SLC7A5FOLH1ADAMTS5POLB | |
| SCHEMBL7163410 | 0.85 | SLC7A5 (0.58) | SLC7A5ESR1ESR2FOLH1TAAR1 | |
| SCHEMBL7163413 | 0.85 | SLC7A5 (0.58) | SLC7A5ESR1ESR2FOLH1TAAR1 | |
| SCHEMBL607090 | 0.83 | SLC7A5 (0.55) | SLC7A5ESR1ESR2FOLH1TAAR1 | |
| SCHEMBL607091 | 0.83 | SLC7A5 (0.55) | SLC7A5ESR1ESR2FOLH1TAAR1 | |
| SCHEMBL7373699 | 0.82 | SLC7A5 (0.54) | SLC7A5ESR1ESR2FOLH1TAAR1 | |
| SCHEMBL31127604 | 0.82 | SLC7A5 (0.54) | SLC7A5ESR1ESR2FOLH1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722228-A1 | NEW COMPOUND TARGETING MUSK AND USE THEREOF | The University of Tokyo (JP) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024248042-A1 | NEW COMPOUND TARGETING MUSK AND USE THEREOF | 国立大学法人 東京大学 | 2024-12-05 | — | — | WO | disclosed |
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230312651-A1 | Cyclic Peptide, Peptide Complex, and Drug Composition Containing Said Cyclic Peptide and/or Said Peptide Complex | THE UNIVERSITY OF TOKYO (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4180446-A1 | CYCLIC PEPTIDE, PEPTIDE COMPLEX, AND DRUG COMPOSITION CONTAINING SAID CYCLIC PEPTIDE AND/OR SAID PEPTIDE COMPLEX | The University of Tokyo (JP) | 2023-05-17 | — | — | EP | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2022232567-A2 | CYCLIC PEPTIDE INHIBITORS OF USP22 | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220275534-A1 | Peptide Library Production Method | THE UNIVERSITY OF TOKYO (JP) | 2022-09-01 | — | — | US | disclosed |
| CN-107428804-B | Immunomodulator | 百时美施贵宝公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114652813-A | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| CN-107108698-B | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3271373-B1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-16 | — | — | EP | disclosed |
| US-6939716-B2 | Method for detecting conditions indicative of sepsis | WASHINGTON UNIVERSITY (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1427845-A2 | METHOD FOR DETECTING SEPSIS | Washington University (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030100122-A1 | Method for detecting conditions indicative of sepsis | WASHINGTON UNIVERSITY | 2003-05-29 | — | — | US | disclosed |
| WO-2003025212-A2 | METHOD FOR DETECTING SEPSIS | WASHINGTON UNIVERSITY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | SLC7A5 3876/4885ESR1 4130/4885ESR2 2136/4885 |
| US-20230312651-A1 | Cyclic Peptide, Peptide Complex, and Drug Composition Containing Said Cyclic Peptide and/or Said Peptide Complex | NPPA, NGLY1, NPR1 | SLC7A5 609/4885ESR1 2608/4885ESR2 2869/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | SLC7A5 3876/4885ESR1 4130/4885ESR2 2136/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | SLC7A5 3876/4885ESR1 4130/4885ESR2 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.